Biodexa Pharmaceuticals Plc
BDRX · NASDAQ
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.04 | -0.00 | 0.00 |
| FCF Yield | -2,076,737.89% | -41.04% | -109.79% | -1,818.14% |
| EV / EBITDA | 0.90 | -3.88 | 0.09 | 2.34 |
| Quality | ||||
| ROIC | -32.56% | -45.69% | -37.56% | -75.70% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -2,612.05% |
| Cash Conversion Ratio | 0.87 | 3.08 | 1.45 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -55.87% | -27.91% | -35.02% | -25.50% |
| Free Cash Flow Growth | 59.82% | -71.17% | -62.02% | 23.63% |
| Safety | ||||
| Net Debt / EBITDA | 0.90 | 0.19 | 1.44 | 2.41 |
| Interest Coverage | -40.16 | 0.00 | -86.18 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -76.43 | -19.59 | -69.44 | 750.82 |